ABSTRACT
ACQ, fears assessment, 327 Adjunctive cognitive-behavioral
therapy (CBT), in preg nancy, 237
Adjunctive lithium, 166 Affectionate constraint, 124 Affectionless control, 124 Agoraphobia, 11, 13, 41, 94, 95,
118 cognitive-behavioral therapy
(CBT) and pharmacother apy, 171
onset, 105 Agoraphobia Cognitions Question
naire (ACQ), 327 Agoraphobic avoidance assess
ment, 327-328 Agoraphobic situations, avoidance
of, 182 Alcohol abuse, 15
Alcohol-causes-panic hypothesis, substance use disorders and PD, 258
Alcohol dependence vs. PD, 255256
Alcoholics, 252-254 benzodiazepines (BZDs) and,
263 Alcoholism, depression and, 103 Alprazolam, 14, 21, 162-165, 210
behavior therapy, 40 Cross National Collaborative
Panic Study, 39 neurochemical abnormalities,
62, 63 PD and comorbid depression, 44 prenatal exposure, 235 quality-of-life studies, 309-310
American Psychiatric Association treatment module, 20
Amitriptyline, pregnancy and, 238 Antecedents, 93-135 Anticipatory anxiety, 45 Antidepressants, 39, 45, 155-161,
166 benzodiazepines (BZDs), 171 discontinuation studies, 42 pregnancy, 230 relapse, 44 selective serotonin-reuptake in
hibitors (SSRIs), 155-159 Antipanic medications
recommended doses, 167t reproductive safety, 233-236
Antipanic treatment, medical condi tions, 168
Anxiety assessment, 328-329 Anxiety difficulties, 46 Anxiety disorders
behavioral inhibition, 112t-113t women, 229-230
Anxiety-management skills, 188189
Anxiety neurosis, 38 Anxiety patients
follow-up, 38 follow-up studies, 38
Anxiety proneness, 105-106 Anxiety sensitivity, 117-119, 185 Anxiety Sensitivity Index (ASI)
factors, 117-118 fears assessment, 326-327
Anxiety state, 38 Anxiogenic effect, benzodiaze
pines (BZDs), 218 Anxiogenic health habits, 212 Arrhythmias, 9-10 ASI
factors, 117-118 fears assessment, 326-327
Assessments, diagnostic and symp tom, 323-335
Asthma, 13 Atenolol, 165 Autonomic Nervous System Ques
tionnaire (ANS), 325 Avoidant coping strategies, 128
Beck Anxiety Inventory (BAI), 328-329
Beck Depression Inventory (BDI), 334
Behavioral Avoidance Tests (BATs), 328
Behavioral experiments, 187-188 Behavioral inhibitions, 48
anxiety disorders, 112t-113t genetic contributions, 108
Behavioral inhibitor experience, 122-123
Behavioral patterns, 120-121 Behavioral tendencies, 120 Behavior therapy, 40 Benzodiazepines (BZDs), 21, 62,
72, 154, 157t, 162-166 abuse-prone individuals, 262-
263 alcoholics, 263 antidepressants, 171 anxiogenic effect, 218 discontinuation, 169 neonatal toxicity, 234-235 pregnancy, 230, 237 prenatal exposure, 234, 235 receptors, 64, 65, 66 treatment resistance, 219,220,221
Beta-blockers, 165, 209 Bodily sensations
interoceptive exposure, 187 misinterpretation, 185, 187
Bodily symptoms and panic provo cation, 186
Body Sensations Questionnaire (BSQ), for fears assess ment, 327
Brain-electrical activity mapping (BEAM), for substance abuse/dependence and PD, 260
Brain regions implicated in PD, 74 Breastfeeding, psychotropic medi
cations and, 238-239 Bupropion, 209 Buspirone, 165, 209 BZD/GABA dysfunction, clinical
relevance, implications, and treatment, 64-66
Caffeine, 60 anxiety production, 168
Calcium channel blocker, treat ment resistance, 220
Candidate genes, 101 Carbamazepine, 209 Cardiology patients, 7 Cardiovascular physiology, clinical
relevance and implications, 73-74
Cardiovascular risk factors, 10 Cardiovascular symptoms, 6-10
quality-of-life studies, 277, 290 CASI, 118-119 Catecholamines, 116 CCK, clinical relevance, implica
tions, and treatment, 66-68 Cerebrospinal fluid, alcoholics and
PD, 259 Cerebrovascular disease, 11 CGIS scores, 163-164 Chest pains, 6
Childhood anxiety disorders, 104107
clinical implications, 134-135 and parental behavior, 124-129 physiological differences, 116-
117 precursors, 104-107 temperament, 107-116 temperamental behavioral inhibi
tion, 111 Childrens Anxiety Sensitivity In
dex (CASI), 118-119 Choking symptoms, 13 Cholecystokinin (CCK), clinical
relevance, implications, and treatment, 66-68
Chronic obstructive pulmonary dis ease (COPD), 14
Clinical Global Impression Im provement and Severity Scales, 158
Clinical Global Impression-Sever ity (CGI-S)
global ratings, 329-330 scores, 163-164, 166
Clinical neurophysiology, rele vance and implications, 70-74
Clinician Global Impression of Im provement (CGI-I), global ratings, 330-331
Clomipramine, 160 vs. paroxetine, 155, 158
Clonazepam, 21, 39, 162-165 prenatal exposure, 235 quality-of-life studies, 309-310 valproate, 221
Clonidine, 166 growth hormone (GH), 59, 60
Cocaine and anxiety production, 168
Cognitive-behavioral interventions, 37, 39, 41-42 (see also Cognitive-behavioral therapy)
Cognitive-behavioral model, 183186, 184f
Cognitive-behavioral therapy (CBT), 14, 154, 181-196
agoraphobia, 171 applications, 193-194 components, 186-189 discontinuation process, 169 follow-up, 41-43 medications, 192
imipramine, 189 selective serotonin-reuptake
inhibitors (SSRIs), 189 tolerance, 214
neurochemical abnormalities, 60, 63
treatment considerations, 186189
treatment-outcome findings, 189-192
pharmacological alternatives, 189
pregnancy, 237 psychopharmacologists, 194-
196 quality-of-life studies, 310-311
Cognitive distortions, 119-120 Cognitive factors, aggravated, 212 Cognitive interventions, exposure,
187 Cognitive restructuring, 187 Cognitive vulnerability factors,
117-121 Combination treatments, 169-171,
191-192, 219t, 221
C0 2 metabolism, clinical rele vance, implications, and treatment, 62-64
Community studies of PD preva lence, 274t-275t
Comorbid depression, 44 Comorbidity contributions, 216 Complex partial seizure disorder,
208 Composite measures, 332-333 Conduct-disordered, 128 Congenital malformations, 235,
236 COPD, 14 Corticotropin-releasing factor
(CRF), 68 Cortisol, salivary, 109 Cost-effectiveness of untreated vs.
